Top

Global Asthma Therapeutics Market 2016-2020

Category : Diagnostic and Biotech  | Published Date : Jul-2016 | Pages : 110
enquire GET DISCOUNT
About Asthma Therapeutics
 
Increasing allergic rhinitis is a major factor for allergic asthma leading to increase in research for the development of allergic immunotherapies for the treatment of asthma. The global asthma therapeutics market will observe a moderate growth during the forecast period because of loss of patent exclusivity of the major drugs, allowing the entry of generics into the market. This will lead to the erosion of the market share of the major asthma drugs. However, the presence of late-stage pipeline molecules will drive the market. An increase in the prevalence of asthma and the use of combination drugs will drive the growth of the market during the forecast period.
 
Technavio’s analysts forecast the global asthma therapeutics market to grow at a CAGR of 4.31% during the period 2016-2020.
 
Covered in this report 
The report covers the present scenario and the growth prospects of the global asthma therapeutics market for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the sales of brand-name, generic, and off-label drugs used for the prevention and treatment of asthma. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from patent expiries of marketed drugs during the forecast period.
 
The market is divided into the following segments based on geography: 
• Americas
• APAC
• EMEA
 
Technavio's report, Global Asthma Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 
 
Key vendors 
• AstraZeneca
• Boehringer Ingelheim
• F. Hoffmann-La Roche
• GSK
• Merck 
Other prominent vendors 
• ALK-Abello
• Amgen
• Array BioPharma
• Asmacure
• Astellas Pharma
• Atopix Therapeutics
• Axikin Pharmaceuticals
• Chiesi Farmaceutici
• Dynavax Technologies Corp.
• Horizon Pharma
• Hovione Scientia
• Invion
• Ivax
• Kissei Pharmaceutical
• Kyowa Hakko Kirin
• MediciNova
• Mitsubishi Tanabe Pharma Corporation
• Mundipharma
• Nycomed
• Oxagen Limited
• Palobiofarma
• Pearl Therapeutics
• Pharmaking
• Pharmaxis
• Pulmagen Therapeutics
• Regeneron Pharmaceuticals
• Revalesio 
• RSPR Pharma AB
• SAMA Pharmaceuticals
• Sanofi
• Skyepharma
• SolAeroMed
• Stallergenes
• Sterna Biologicals
• Synairgen
• Theron Pharmaceuticals
• UCB Pharma
• Vectura
• Verona Pharma
• Whanin Pharmaceutical Company 

Market driver 
• Huge market potential for mAbs
• For a full, detailed list, view our report 
 
Market challenge 
• Increased preference for CAM
• For a full, detailed list, view our report 
 
Market trend 
• Innovative technologies for drug delivery
• For a full, detailed list, view our report 
 
Key questions answered in this report 
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors? 
 
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.





PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
• Breakthrough in asthma research
• Asthma: An overview
PART 05: Pipeline portfolio
PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 07: Key buying criteria for asthma drugs
PART 08: Market segmentation by type of treatment
• Preventive medications
• Quick-relief medications
• Others
PART 09: Market segmentation by drug class
• Combination therapies
• Bronchodilators
• Immunosuppressants
• Leukotriene antagonists
• Mast cell stabilizers
PART 10: Segmentation by route of administration
• Inhalation
• Parenteral
• Oral
PART 11: Drug delivery devices market for asthma drugs
• Market overview
• Market segmentation by product type
PART 12: Geographical segmentation
• Global asthma therapeutics market by geography 2015-2020
• Asthma therapeutics market in Americas
• Asthma therapeutics market in EMEA
• Asthma therapeutics market in APAC
PART 13: Market drivers
• Huge market potential for mAbs
• New product approvals minimizing the impact of generic erosion
• Increasing rate of allergies due to environmental pollution
PART 14: Impact of drivers
PART 15: Market challenges
• Increased preference for CAM
• Poor patient adherence toward controller medications
• Presence of different phenotypes of asthma leading to prescription errors
PART 16: Impact of drivers and challenges
PART 17: Market trends
• Innovative technologies for drug delivery
• Growing adoption of immunotherapies
• Shift toward immune/inflammatory system targets from glucocorticoid and adrenergic receptors
• Increase in online marketing services
• Growing use of home healthcare devices
PART 18: Vendor landscape
• Competitive scenario
• Key news
PART 19: Key vendor analysis
• AstraZeneca
• Boehringer Ingelheim
• F. Hoffmann-La Roche
• GSK
• Merck
• Other prominent vendors
PART 20: Appendix
• List of abbreviations
PART 21: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Breakthrough in asthma research
Exhibit 03: Major diagnostic procedures for asthma
Exhibit 04: Percentage share of pipeline molecules based on stage of development
Exhibit 05: Pipeline portfolio: Global asthma therapeutics market
Exhibit 06: Global asthma drugs market: Market overview 2015
Exhibit 07: Global asthma therapeutics market 2015-2020 ($ billions)
Exhibit 08: Global asthma drugs market snapshot: Developed and emerging markets 2015
Exhibit 09: Global asthma therapeutics market: Key parameters driving the market growth 2015
Exhibit 10: Five forces analysis
Exhibit 11: Key buying criteria for asthma drugs
Exhibit 12: Global asthma therapeutics market: Key parameters importance
Exhibit 13: Impact of key customer segments on market
Exhibit 14: Segmentation of asthma drugs based on type of treatment
Exhibit 15: Segmentation of asthma drugs based on drug class
Exhibit 16: Percentage share of global asthma therapeutics by drug class based on revenue 2015
Exhibit 17: Global asthma therapeutics market: Drug class segmentation growth cycle analysis 2015
Exhibit 18: Combination therapies market in global asthma therapeutics market 2015-2020 ($ billions)
Exhibit 19: Bronchodilators market in global asthma therapeutics market 2015-2020 ($ billions)
Exhibit 20: Percentage share of allergy immunotherapies and steroids in global immunosuppressants market 2015
Exhibit 21: Immunosuppressants market in global asthma therapeutics market 2015-2020 ($ billions)
Exhibit 22: Leukotriene antagonists market in global asthma therapeutics market 2015-2020 ($ billions)
Exhibit 23: Mast cell stabilizers market in global asthma therapeutics market 2015-2020 ($ billions)
Exhibit 24: Segmentation of global asthma therapeutics market by route of administration
Exhibit 25: Global asthma drug delivery devices market 2015-2020 ($ millions)
Exhibit 26: Global asthma drug delivery devices market segmentation by product type
Exhibit 27: Percentage share of global asthma drug delivery devices by type 2015
Exhibit 28: Percentage share of inhalers in global asthma drug delivery devices market 2015
Exhibit 29: Inhalers market in global asthma drug-delivery devices market 2015-2020 ($ millions)
Exhibit 30: Percentage share of nebulizers in global asthma drug delivery devices market 2015
Exhibit 31: Nebulizers market in global asthma drug-delivery devices market 2015-2020 ($ millions)
Exhibit 32: Global asthma therapeutics market by geography 2015-2020
Exhibit 33: Percentage share of global asthma therapeutics market by geography 2015 and 2020
Exhibit 34: Global asthma therapeutics market segmentation by geography 2015-2020 ($ billions)
Exhibit 35: Global share of asthma therapeutics market by geography 2015
Exhibit 36: Global asthma therapeutics market: Country analysis based on revenue and growth rate
Exhibit 37: Impact of ACA act on asthma therapeutics market
Exhibit 38: Asthma therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 39: Asthma therapeutics market: PEST analysis
Exhibit 40: Prevalence of asthma in major countries of EMEA
Exhibit 41: Asthma therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 42: Asthma therapeutics market in EMEA: PEST analysis
Exhibit 43: Asthma therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 44: Asthma therapeutics market: PEST analysis
Exhibit 45: mAbs approved for treatment of asthma
Exhibit 46: mAbs under development for treatment of asthma
Exhibit 47: Impact of drivers
Exhibit 48: Use of CAM therapies among individuals in US
Exhibit 49: Impact of drivers and challenges
Exhibit 50: Market share of major vendors based on asthma therapeutics revenue 2015
Exhibit 51: Competitive scenario of global asthma therapeutics market vendors 2015-2020
Exhibit 52: Geographical presence of key vendors
Exhibit 53: AstraZeneca: YoY revenue and growth rate of Symbicort 2013-2015 ($ billions)
Exhibit 54: AstraZeneca: Geographical segmentation of Symbicort 2015
Exhibit 55: AstraZeneca: YoY revenue and growth rate of Pulmicort 2013-2015 ($ millions)
Exhibit 56: AstraZeneca: Geographic segmentation of Pulmicort 2015
Exhibit 57: AstraZeneca: Metrics analysis
Exhibit 58: Boehringer Ingelheim: YoY revenue and growth rate of Spiriva 2013-2015 ($ billions)
Exhibit 59: Boehringer Ingelheim: Metrics analysis
Exhibit 60: F. Hoffmann-La Roche: YoY revenue and growth rate of Xolair 2012-2014 ($ millions)
Exhibit 61: F. Hoffmann-La Roche: Metrics analysis
Exhibit 62: GSK: YoY revenue and growth rate of Seretide/Advair 2013-2015 ($ billions)
Exhibit 63: Geographical segmentation of Seretide/Advair 2015
Exhibit 64: GSK: YoY revenue and growth rate of Flixotide/Flovent 2013-2015 ($ billions)
Exhibit 65: GSK: Geographical segmentation of Flixotide/Flovent 2015
Exhibit 66: GSK: YoY revenue and growth rate of Ventolin 2013-2015 ($ billions)
Exhibit 67: GSK: Geographical segmentation of Ventolin 2015
Exhibit 68: GSK: YoY growth and revenue of Relvar/Breo Ellipta 2014-2015 ($ millions)
Exhibit 69: GSK: Geographical segmentation of Relvar/Breo Ellipta 2015
Exhibit 70: GSK: Metrics analysis
Exhibit 71: Merck: YoY growth and revenue of Singulair 2013-2015 ($ millions)
Exhibit 72: Merck: YoY growth and revenue of Dulera 2013-2015 ($ millions)
Exhibit 73: Merck: Metrics analysis0
...
Publisher Name : Technavio

SIMILAR MARKET STUDIES

Please Select Format
Single User: US $ 2500
Five User: US $ 3000
Site User: US $ 4000
Global User: US $ 10000

NEED MORE INFORMATION
Contact us
Call us +1-971-202-1575
--- or ---
help@bigmarketresearch.com
WHY BIG MARKET RESEARCH
With high quality and penned to perfection, Big Market Research is an exclusive online market to get best market research reports for your business needs and strategies. We recommend you to stop browsing as soon as you discover our website. This is because we firmly believe that once you reach here; all your business concerns will be addressed.

We have a huge collection of market research report from numerous filed which will provide you with all the necessary solution. We make sure that reports that we sell are true in context, have a quality that is unrivaled, fully integrated with equal spread of opinion. They will give you proper insights into different opportunities one may locate for their start-up pr expansion.

Let your qualms and concern be sidelined through our high end syndicated as well as customized reports.
Top